Cara Therapeutics, Inc. Stock price

Equities

CARA

US1407551092

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.91 USD +4.72% Intraday chart for Cara Therapeutics, Inc. +2.06% +22.48%
Sales 2024 * 5.59M Sales 2025 * 3.67M Capitalization 49.74M
Net income 2024 * -64M Net income 2025 * -81M EV / Sales 2024 * 7.04 x
Net cash position 2024 * 10.4M Net Debt 2025 * 29.1M EV / Sales 2025 * 21.5 x
P/E ratio 2024 *
-0.78 x
P/E ratio 2025 *
-0.81 x
Employees 55
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.41%
More Fundamentals * Assessed data
Dynamic Chart
Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating MT
Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M MT
North American Morning Briefing : Stock Futures -2- DJ
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit MT
Transcript : Cara Therapeutics, Inc. - Special Call
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program CI
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024 CI
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating MT
Top Midday Decliners MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating MT
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis CI
Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from NASDAQ Biotechnology Index CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching MT
More news
1 day+4.72%
1 week+2.06%
Current month+7.03%
1 month+2.25%
3 months+18.61%
6 months-46.15%
Current year+22.48%
More quotes
1 week
0.72
Extreme 0.723
0.96
1 month
0.72
Extreme 0.723
1.15
Current year
0.50
Extreme 0.5
1.15
1 year
0.50
Extreme 0.5
5.20
3 years
0.50
Extreme 0.5
29.65
5 years
0.50
Extreme 0.5
29.65
10 years
0.50
Extreme 0.5
29.65
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-08-05
Director of Finance/CFO 54 22-09-11
Chief Tech/Sci/R&D Officer 50 18-10-22
Members of the board TitleAgeSince
Chairman 60 10-06-30
Director/Board Member 73 14-07-15
Director/Board Member 58 23-08-01
More insiders
Date Price Change Volume
24-03-28 0.91 +4.72% 637,279
24-03-27 0.869 +19.01% 569,385
24-03-26 0.7302 -10.94% 711,831
24-03-25 0.8199 -7.18% 470,713
24-03-22 0.8833 -0.93% 204,803

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.91 USD
Average target price
4.9 USD
Spread / Average Target
+438.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Cara Therapeutics, Inc. - Nasdaq